Drug Trial Radar · NCT03794557
The Effect of Inhaled PUL-042 on Rhinovirus-induced Symptoms in Smokers With GOLD Stage 0 COPD
Last checked: Nov 19, 2026Latest source record: Jun 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Jan 21, 2019
Primary completion
Dec 16, 2020
Study completion Mar 23, 2021
Sponsor
- Lead sponsor
- Pulmotect, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Imperial College Healthcare NHS Trust; VirTus Respiratory Research Ltd; MWB Consulting Ltd; Data Magik Ltd
- First posted
- Jan 7, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study examining the effect of inhaled PUL-042 on peak lower respiratory symptoms as measured by subject diary in early stage COPD subjects who are experimentally infected with rhinovirus. Subjects will receive 1 dose of PUL-042 followed by inoculation with HRV A16 virus 24 hours later. An additional dose of PUL-042 will be administered 48 hours post-inoculation. Subjects will be followed for 6 weeks post-inoculation
Conditions
- COPD
Interventions
Sterile Water InjectionDrug
Inhaled Sterile Water Injection
PUL-042 Inhalation SolutionDrug
PUL-042 Inhalation Solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Lower Respiratory Symptom Score as measured by Mallia et al (Am J Respir Crit Care Med. 2011)Time frame: Daily Scores Day 0-42
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Imperial College Healthcare NHS Trust, St Mary Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.